Virtual access - The invisible impact of COVID-19 on hypermobility syndromes and neurodivergence- bodies, brains and burnout

Join us online for an in-depth exploration of the links between Generalised Joint Hypermobility (GJH), hypermobility Ehlers-Danlos Syndromes (hEDS) and the closely related Hypermobility Spectrum Disorders (HSD), with post-COVID health complications, henceforth described as hypermobility. We will explore the concept of “Bendy-Brain”, linking Hypermobility with multi-organ involvement (gastrointestinal, genitourinary, cardiovascular, autonomic nervous system, neurodivergence, and brain) in susceptible patients. Please scroll down to view the full agenda. 

We will learn about the genetics, immunology, and cytokine cascades, MCAS, and resulting dysregulation of the autonomic nervous system, GI tract, and multiple organs. The impact and importance of co-occurring neurodivergent conditions is also discussed, and the wider implications for health and education. We learn how to treat the histamine overload and dysautonomia and the resulting escalation of chronic fatigue and pain/fibromyalgia with new treatments. We also look at spike protein retention and how this might be the ultimate trigger. We will explore recent research on the origins and exacerbation of these widespread, persistent health issues, alongside potential solutions to restore patients’ well-being.

COVID-19 has disproportionately impacted patients with hypermobility conditions.  hEDS / HSD is  a heritable connective tissue disorder with weakened proteins like collagen found throughout the body. We ascertain that around 20% of the UK population, 14 million people, are susceptible to injury or illness due to having symptomatic hypermobility.

Recent studies show that those with GJH as a risk factor and already with it are 30% less likely to recover from COVID-19 infection. Post-COVID, we can still see the ongoing 'fall out' of hypermobile and neurodivergent patients. Particularly young, working-age people are rendered disabled and more women are affected than men.

This is a must-attend online event for medical professionals, researchers, policy makers, educators, and patient advocates seeking to enhance their understanding of hypermobility and its complex interplay with post-COVID conditions. Attendees will gain valuable insights into early diagnosis, specialist care, and targeted interventions such as neuromodulation for fibromyalgia and chronic pain. The programme will also cover emerging therapies, lifestyle interventions, and the latest advancements in personalised patient management. Don’t miss this opportunity to stay ahead in the field and contribute to the ongoing dialogue on improving care for those with Hypermobility.

By attending, you will:

1. Aim to identify conditions that increase susceptibility to post-COVID symptoms.
2. Explore innovative treatments, medications, and lifestyle interventions to enhance patient well-being.
3. Gain a deeper understanding of GJH, hEDS, and HSD and their effect on multi-organ systems.
4.  Understand neuromodulation as a treatment for pain and fibromyalgia.
5. Advocate for NHS resources and funding to establish a dedicated treatment base for all affected patients.

Follow us on:

Facebook 
Instagram
LinkedIn
Twitter
YouTube